Prostate cancer in Asia: design of a patient registry to inform real-world treatments, outcomes, and quality of life

Abstract

Background The incidence of prostate cancer (PC) in Asian countries is increasing for reasons that are not clear. Data describing how PC is diagnosed and treated are fragmented across Asia, with marked intercountry and intracountry differences in outcome and knowledge gaps in clinical diagnostic and treatment practices. To address these knowledge gaps, we have established a PC disease registry with the aim of providing a comprehensive picture of PC diagnosis, prognosis, treatment and outcome, population characteristics, and comorbidities in real-world clinical practice in Asia. Methods This is a multinational, multicenter, longitudinal, and observational registry of PC patients presenting to participating tertiary-care hospitals in eight Asian countries ( www.clinicaltrials.gov NCT02546908. Registry Identifier: NOPRODPCR4001). Approximately 3500-4000 eligible patients with existing or newly diagnosed high-risk localized PC (cohort 1), nonmetastatic biochemically recurrent PC (cohort 2), or metastatic PC (cohort 3) will be consecutively enrolled and followed-up for 5 years. An enrollment cap of 600 patients each will be applied to cohorts 1 and 2. Disease status is collected at enrollment, and outcome variables captured at 3-monthly intervals include diagnostic/staging, treatments including reason for change, laboratory results, comorbidities, and concomitant medications. Treatments and survival outcomes will be captured real time until study end. Patient-reported quality-of-life will be measured every 6 months, and medical resource utilization summarized at study end. Data analysis will include exploratory analyses of potential associations between multiple risk factors and socioeconomic variables with disease progression and evaluation of various treatments for PC including novel therapies on clinical outcome and health-related quality-of-life outcomes. Results 3636 men with PC were enrolled until July 2018; 416 in cohort 1, 399 in cohort 2 and 2821 in cohort 3. Discussion A total of 3636 patients were enrolled until July 2018. The prospective disease registry will provide comprehensive and wide-ranging real-world information on how PC is diagnosed and treated in Asia. Such information can be used to inform policy development for best practice and direct clinical study design evaluating new treatments.

Landscape of Carbon Ion Radiotherapy in Prostate Cancer: Clinical Application and Translational Research

“…Prostate cancer is a common malignant tumor, and although the incidence in Asia is lower than that in Europe and the United States, the incidence is on the rise and the survival rate is lower than that in Europe and the United States, adding to the burden on society and families (57). Radiotherapy is one of the main treatment modalities for prostate cancer, and photon radiotherapy is currently used in clinical practice (12).…”

United in Fight against prOstate cancer (UFO) registry: first results from a large, multi‐centre, prospective, longitudinal cohort study of advanced prostate cancer in Asia

“…The registry design has been described in detail by Liu et al (http://www.clinicaltrials.gov NCT02546908, Registry Identifier: NOPRODPCR4001). In brief, ~3500 eligible patients with existing or newly diagnosed high‐risk localised prostate cancer (HRL), non‐metastatic biochemically recurrent prostate cancer (M0), or metastatic prostate cancer (M1), were to be enrolled and followed for up to 5 years.…”

Prostate cancer in multi‐ethnic Asian men: Real‐world experience in the Malaysia Prostate Cancer (M‐CaP) Study

“…The Japanese Study Group of Prostate Cancer (J‐CaP) was established as a nationwide longitudinal prospective cohort study in 2001 to assess the outcomes of prostate cancer patients undergoing androgen deprivation therapy (ADT) 4 . In 2015, the United in Fight against Prostate Cancer (UFO) registry was commenced focusing on the management and patient‐reported quality of life of advanced prostate cancer in eight Asian countries 5 . The availability of longitudinal, observational prostate cancer database remains scarce in this part of the world.…”